Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region by �꽌�씪
Published by Oxford University Press on behalf of the International Epidemiological Association International Journal of Epidemiology 2005;34:1036–1045
© The Author 2005; all rights reserved. Advance Access publication 24 May 2005 doi:10.1093/ije/dyi104
Smoking, quitting, and the risk of
cardiovascular disease among women
and men in the Asia-Pacific region
Asia Pacific Cohort Studies Collaboration†*
Accepted 21 April 2005
Background Although smoking is a major risk factor for cardiovascular disease, it has been
suggested that Asians may be less susceptible to the adverse effects of smoking
than Caucasians. This may have contributed to the high prevalence of smoking,
and the low quitting rates, in Asian men. Worldwide, smoking rates are increasing
for women, amongst whom cardiovascular awareness is relatively poor.
Methods An individual participant data analysis of 40 cohort studies was carried out,
involving 463 674 Asians (33% female) and 98 664 Australasians (45% female).
Cox proportional hazard models, stratified by study and sex where appropriate,
were employed.
Results The HR [95% confidence interval (CI)], comparing current smokers with non-
smokers, for coronary heart disease (CHD) was 1.60 (1.49–1.72); haemorrhagic
stroke 1.19 (1.06–1.33); ischaemic stroke 1.38 (1.24–1.54). There was a clear
dose–response relationship between the number of cigarettes smoked per day
and both CHD and stroke, with no significant difference (P  0.20) between
populations from Asia and Australia/New Zealand. Although there was no sex
difference for stroke in the effect of amount smoked (P = 0.16), for CHD, women
tended to have higher hazard ratios than men (P = 0.011). Quitting gave a clear
benefit, which was not significantly different between the sexes or regions
(P  0.63). The HR (CI) for ex-smokers compared with current smokers was 0.71
(0.64–0.78) for CHD and 0.84 (0.76–0.92) for stroke.
Conclusions Unless urgent public health measures are put into place, the impact of the
smoking epidemic in Asia, and among women, will be enormous. Tobacco
control policies that specifically target these populations are essential.
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Smoking is well known as a major risk factor for cardiovascular
disease (CVD).1 However, a question remains regarding the
relative strength of the association within ethnic, age, and sex
subgroups. Most importantly, there has been some suggestion
that Asians may have less excess risk from smoking than
Caucasians,2 which may have contributed to the huge
percentage of people (largely men) who now smoke in several
Asian countries.3 Given that one third of all cigarettes are
smoked in China alone,4 reliable data on the risks of smoking in
Asia, and how they relate to risks elsewhere, are crucial but
currently lacking. Information on age and sex differences are
important for targeting health promotion activities, especially as
smoking among young females has been on the rise in many
populations.4 A related issue is whether smoking has different
effects for the three major components of CVD: coronary heart
disease (CHD), ischaemic, and haemorrhagic stroke. In terms
of total CVD events, Asian populations have a greater percent-
age of strokes, while among all strokes they have a greater
percentage of haemorrhagic strokes than European and North
American populations.5
To address these issues we analysed data from the Asia Pacific
Cohort Studies Collaboration (APCSC), providing the largest
individual participant data meta-analysis from this region to date.
Methods
The Asia Pacific Cohort Studies Collaboration is an overview
of cohort studies in the region. As studies were recruited
retrospectively, study protocols and conduct differ between
studies. Details of study identification, data collection, and event
verification are described elsewhere.6,7 All studies in APCSC
were conducted prospectively in a population from the Asia-
Pacific region, continued follow-up for at least 5000 person-
years, and recorded age, sex, and blood pressure at baseline and
vital status at the end of the follow-up. Studies were excluded
if entry was dependent upon having a particular condition
or risk factor. A variety of methods were used to ascertain
outcomes, involving monitoring, re-surveying and/or record
linkage; in some studies non-fatal, as well as fatal,
cardiovascular outcomes were recorded.
All data on cigarette smoking were self-reported at the time
when the subject entered the study. All studies included here
recorded current cigarette smoking status: yes/no. Some studies
additionally recorded whether individuals were current, 
ex-smokers or never-smokers, and some recorded cigarettes per
day for smokers. Most studies additionally measured, at the
same time, total cholesterol (from serum) and body mass index
[BMI: weight (kg) divided by squared height (m2)]. Studies
were classified as Asian if the participants were recruited from
mainland China, Hong Kong, Japan, Korea, Singapore, Taiwan
or Thailand and as ANZ if the participants were from Australia
or New Zealand.
All outcomes were classified, after recoding when necessary,
according to the ninth revision of the International
Classification of Diseases (ICD): CHD (ICD 410–414); stroke
(430–438); haemorrhagic stroke (431.0–432.9); ischaemic
stroke (433.0–434.9); and all CVD (390–459). Deaths were
ascribed solely to their underlying cause. For studies that
collected data on both non-fatal and fatal events, the composite
outcome was analysed.
Analyses used individual participant data, and were restricted
to individuals aged 20 years at the time of the baseline survey
for whom smoking status was recorded. Cox proportional
hazards models, stratified by study and (where appropriate) sex,
and adjusted for age and systolic blood pressure were used to
estimate hazard ratios (approximate relative risks) associated
with smoking. In some analyses, further adjustments were
made for total cholesterol and BMI, which, unlike blood
pressure, were missing for some participants. Homogeneity
between groups defined by geographical area (Asia/ANZ),
sex, and age groups was investigated by adding interaction
terms to the Cox model. Confidence limits for dose–response
hazard ratios were calculated using the floating absolute risk
method,8 using four ordinal cigarette consumption groups:
0, 20, 20, and 20 cigarettes per day. These groups were
chosen so as to provide as near an equal four-way partition
as possible (20 cigarettes corresponds to one standard pack). A
random effects meta-regression8 was used to relate log hazard
ratios from Cox models to follow-up durations using individual
study data.
Results
Of the 43 studies in APCSC, 40 (32 in Asia; 8 in ANZ) provided
data on current smoking status, of which 33 distinguished ex-
smokers from never-smokers and 23 provided data on cigarette
consumption for current smokers (Table 1). Total person-years
of follow-up were 1.3 million for smokers and 1.7 million for
non-smokers in Asia, with corresponding figures of 177 000
and 702 000 in ANZ. Altogether, 8490 deaths from CVD and
a further 3972 non-fatal MI or stroke events were recorded
(Table 2). As expected, strokes outnumbered CHD only in Asia,
whilst haemorrhagic strokes made up a greater percentage of all
strokes in Asia compared with ANZ.
Current smoking was a significant predictor of all types of
cardiovascular events; it was most strongly related to CHD and
ischaemic stroke, where smokers had ~50% greater risk of an
event than non-smokers (Figure 1). There were no significant
differences in the relative effect of smoking on CHD or stroke
between Asia and ANZ or between women and men, but some
evidence of a decline in relative effect with age, leading to small
effects in those aged 75 years (Figure 2). Additional
adjustments for cholesterol and BMI made no substantive
difference to the results (data not shown). The hazard ratio for
CHD increased by 1% in both Asia and ANZ after extra
adjustment for cholesterol and by 3% in Asia and 4% in ANZ
after both adjustments. When Asian studies were subdivided by
country, no statistical differences were noted. The hazard ratio
(95% CI) relating smoking to CHD was 1.53 (1.30–1.81) in
mainland China, 1.45 (1.12–1.87) in Korea, and 1.92
(1.44–2.56) in Japan. Corresponding results for stroke were
1.24 (1.13–1.37), 1.34 (1.17–1.54), and 1.38 (1.16–1.64).
For those studies that distinguished ex-smokers from never-
smokers, the CHD hazard ratio (95% CI) for current compared
with never-smoking was 1.75 (1.60–1.90), and for ex-smoking
compared with current smoking was 0.71 (0.64–0.78). For
stroke, these results were 1.43 (1.32–1.54) and 0.84
(0.76–0.92), respectively. There were no significant differences
by region (P = 0.68 for CHD and 0.90 for stroke) or by sex
(P = 0.95 for CHD and 0.63 for stroke).
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Table 2 Number of events in each study
Fatal events Non-fatal events
Study CVD CHD Stroke Haem Isch MI Stroke Haem Isch
ANZ
Busselton 1200 685 261 35 40 461 486 27 93
Longitudinal Study of 214 81 52 8 7
Aging
Melbourne 551 323 100 35 11
National Heart Foundation 115 77 17 0 2
Newcastle 204 137 34 9 3
Perth 313 195 63 10 4
WA AAA Screenees 359 240 60 16 7 82 167 15 106
Fletcher Challenge 171 114 24 1 3 177 179 8 65
Subtotal 3127 1852 611 114 77 720 832 50 264
Asia
Anzhen 192 65 98 52 40 103 18 80
Anzhen02 2 1 1 1 0 15 14
Beijing Aging 204 86
Capital Iron & Steel Co 103 35 68 48 15 54 108 22 81
CISCH 1 1 14 9
East Beijing 65 20 28 11 14
Fangshan 23 0 11 4 3 5 23 4 17
Guangzhou Occupational 567 166 262 167
Seven Cities Cohorts 512 84 186 140 38 143 53 88
Shanghai Factory Workers 390 86 255
Six Cohorts 288 27 120 83 26 21 116 22 89
Tianjin 669 96 298 156 34 18 123 33 90
Xi’an 80 35 41 24 15
Yunnan 222 18 106 93 12
Hong Kong 202 86 73 16 6
Akabane 35 7 12 1 9 21 26 4 7
Civil Service Workers 12 1 2 1
Hisayama 302 53 177 54 99 53 222 17 193
Konan 24 2 12 3 7
Miyama 24 2 10 1 6
Ohasama 27 7 8 2 4 48 9 35
Saitama 119 24 55 15 27
Shibata 346 67 209 36 77
Shigaraki Town 28 3 13 2 4
Shirakawa 162 45 72 28 28 22 32 4 25
Tanno/Soubetsu 73 24 33 16 10
Singapore Heart 59 31 21 4 2 39 67 3 20
Singapore NHS92 33 22 6 2 2 15 41 2 12
KMIC 383 94 198 110 33 191 891 226 407
CVDFACTS 60 13 29 8 7
Kinmen 105 10 14
EGAT 51 33 16
Subtotal 5363 1158 2520 1078 518 453 1967 417 1158
Total 8490 3010 3131 1192 595 1173 2799 467 1422
ANZ, Australia/New Zealand; CVD, cardiovascular disease; CHD, Coronary heart disease; Haem, Haemorrhagic stroke; Isch, Ischaemic stroke; MI, Myocardial
infarction. Blanks denote no data available.
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Figures 3 and 4 show a positive dose–response relationship
between the number of cigarettes smoked and the hazard
ratio for CHD and stroke for each of Asians, those in ANZ,
women and men. Although hazard ratios for any level of
cigarette smoking, compared with non-smokers, are always
lower in Asia than in ANZ, this difference does not reach
traditional levels of statistical significance for CHD or stroke
(Figure 3). For both CHD and stroke, hazard ratios comparing
smokers of 20 cigarettes per day with non-smokers are
much higher for women than men (Figure 4). However, the
Figure 1 Hazard ratios (on the log scale) with 95% confidence intervals (CIs) for various cardiovascular events (fatal or non-fatal), comparing
current smokers with non-smokers. Hazard ratios are adjusted for age and systolic blood pressure after stratification by sex and study. The
horizontal lines and width of diamond are 95% confidence limits; the boxes are drawn in proportion to the number of events. CHD, coronary
heart disease; CVD, cardiovascular disease
Figure 2 Hazard ratios, adjusted for age and systolic blood pressure, for (a) coronary heart disease and (b) stroke, comparing current smokers
with non-smokers, among demographic subgroups. Conventions as in Figure 1. P values are shown for tests of homogeneity between subgroups
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overall sex difference in the risk by smoking amount is only
statistically significant (P = 0.011) for CHD. The region and
sex comparisons stratified by dose of smoking in Figures 3 and
4 are likely to be more meaningful than those that ignore
the amount smoked in Figure 2. The lower mean daily
cigarette consumption among female smokers (10 in Asia; 15 in
ANZ) compared with male smokers (16 and 20, respectively)
explains the contrasting findings in Figure 2 (which shows
no sex difference when comparing current smokers with 
non-smokers) and Figure 4 (which shows greater risk for
women with high consumption, when comparing according to
amount smoked).
As a sensitivity analysis, all the results in Figures 1–4 were
reproduced for fatal events only. In every case the hazard ratios
were similar and the patterns shown by the plots were
unchanged (data not shown).
Discussion
The results from this, the largest ever study of smoking in the
Asia-Pacific region, and one of the largest anywhere in the
world, confirm that cigarette smoking is a risk factor for both
CHD and stroke, independent of the effects of BMI, blood
pressure, and cholesterol, with ameliorations of the effects after
Figure 4 Hazard ratios, adjusted for age and systolic blood pressure, for (a) coronary heart disease and (b) stroke by number of cigarettes per day
smoked (base = non-smoker), for women and for men. Bars show 95% CIs calculated using the floating absolute risk method. P values are shown
for tests of homogeneity between women and men
Figure 3 Hazard ratios, adjusted for age and systolic blood pressure, for (a) coronary heart disease and (b) stroke by number of cigarettes per day
smoked (base = non-smoker), for Asia and for Australia and New Zealand (ANZ). Bars show 95% CIs calculated using the floating absolute risk
method. P values are shown for tests of homogeneity between Asia and ANZ
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quitting. Importantly, the results also show that smoking is an
independent risk factor for haemorrhagic stroke, the most
common type of stroke in Asia and more likely than ischaemic
stroke to lead to death within 28 days.5 The large numbers
involved make the overall estimates of the relative effects of
smoking more precise than those in most previous studies. Our
results also show that younger people and women have greater
relative risks of CVD from smoking than others. Most
importantly, we find that Asians and the predominantly
Caucasian Australians and New Zealanders have similar
increased proportional cardiovascular risk from smoking
cigarettes and similar relative risk reduction from quitting.
Our findings of greater relative risks for CHD from smoking for
women than men are in agreement with recent literature.9–13
Although one study from the west of Scotland has shown lack
of difference between the sexes,14 it contradicts a national
Scottish study of comparable size.11 Past estimates of such
differences have rarely been as precise. One study that is larger
than ours is the American Cancer Society Cancer Prevention
Study II, which showed, both for CHD and stroke, greater
relative risks (current vs never-smokers) for women compared
with men at all ages, as well as a steady decline in relative risk
with age,15 as we find in APCSC. Possibly women experience an
anti-oestrogenic effect from smoking, as well as the thrombogenic
effect experienced by both men and women.16
The overall lack of regional differences in relative risks, and
the moderate differences by sex when comparing all smokers
with non-smokers, might be contrasted with the large
differences in attributable risks. Taking typical current
prevalences3 of smoking across Asia to be 70% in men and 5%
in women, the attributable risk for CHD from smoking is ~30%
in men and 3% in women,8 using the overall age and blood
pressure-adjusted hazard ratio for CHD from Figure 1.
Equivalent figures for stroke are 18 and 2% for men and women,
respectively. In ANZ, assuming 25% current prevalence in men
and 20% in women,3 the results for CHD are 13 and 11% for
men and women, respectively, and the results for stroke are 7
and 6% for men and women, respectively. Trends in smoking
should make numbers converge in the future.
This study has a major advantage of being very large;
however, it has a number of disadvantages. Few variables on
smoking habits are included in the Collaboration. Relative risks
relating to cigarette smoking may vary by type of cigarette
smoked (filter/not; black/blond tobacco; hand rolled/
manufactured; etc.) and inhalation habits. These may well vary
by region, age, and sex.
As no data were collected on lifetime smoking, we cannot
take duration of smoking into account when making
comparisons between regions, age groups, or the sexes. Since
smoking is generally longer established in ANZ than Asia, in
men than women, and in older than younger people, our
analyses of current smoking will have relatively underestimated
the true relative risk of current smoking for Asians, women, and
younger people. Although we have shown no significant
difference between the relative risks of smoking on CHD and
stroke for Asians and Caucasians, we did find lower relative
risks for Asians at each level of cigarette smoking. In APCSC, we
can only estimate the effects of differences in smoking duration
during follow-up, which is but one component of the overall
effect of smoking duration. The median follow-up in Asian
APCSC studies (6.3 years) was 2 years shorter than in ANZ
studies (8.3 years). From a meta-regression8 of log hazard ratios
against median follow-up in APCSC we estimated that the
hazard ratio (95% CI) for CHD would be increased by 2.0%
(0.02–3.7%) for each extra year of follow-up. Thus, as found in
the British Doctors Study,17 relative risks for smoking tend to
increase as duration of follow-up increases, and we would
expect to find smaller relative risks in our studies from Asia,
compared with ANZ, even if the effect of smoking was
homogeneous across regions. Furthermore, the immaturity of
the smoking epidemic in Asia, compared with ANZ, suggests
that Asian smokers may tend to be of relatively high social class
compared with smokers in ANZ. Thus we would also expect
that adjustments for other cardiovascular risk factors,
unmeasured in our study, would reduce the differentials in
relative risks for smoking between Asia and ANZ.
No objective measures of tobacco consumption were available
in the APCSC database. These have been shown to have
important advantages over self-reports in CVD research when
there are many self-reported quitters,18 as indeed there are in the
ANZ, though not the Asian, cohorts in APCSC (Table 1). Another
restriction is that the current analyses only use smoking habits
recorded at baseline; changes in habit over the duration of follow-
up were available from so few studies that no meaningful analysis
could be undertaken. However, when we restricted analyses to 1,
2, and 3 years follow-up, where changes in smoking status would
be expected to be relatively few, there were no important
differences in the ratio of relative risks, comparing Asia with ANZ.
Finally, differences between studies may have biased the
results in some unknown way. The individual studies used
different laboratory and physical examination methods, which
will compromise the statistical adjustments for blood pressure,
cholesterol, and BMI. Furthermore, different methods were
used to verify outcomes. In particular, only 57% of fatal strokes
were classified by subtype, and, while most strokes should
have been verified by imaging or autopsy, we have limited
information from many studies.
Our data provide precise estimates of the relative impact of
smoking upon cardiovascular health in the Asia-Pacific region,
where data previously have been scarce,19 thus avoiding the
need for indirect estimation of the public health impact of
smoking.20 The Asian results here mainly agree with recent
reports from Asia,21–23 except that two Japanese studies have
reported a protective effect of smoking for haemorrhagic
stroke.24,25 This may possibly be explained by chance findings
with smaller sample sizes or differences in the make-up of this
heterogeneous disease.5,22,24 Our results underline the
observations made by previous authors4,25,26 that if smoking
goes unchecked, the impact of smoking upon health in Asia,
and particularly China, will be huge.
We found no difference in the reductions in risk of CVD, for
those who have stopped smoking, between Asians and Caucasians.
Taken together with a recent meta-analysis,27 which showed no
ethnic differences in the benefit of quitting among those who had
previous coronary disease, this suggests that there will be real
benefit, in huge absolute numbers, from campaigns to promote
quitting in Asia. Previous evidence of the benefits of quitting
among Asians is scarce, largely because it happens so rarely (see,
for example, Table 1). Unfortunately, in some parts of Asia there is
a common belief that sudden quitting after long-term smoking
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may be harmful.28 Higher risks among ex-smokers, compared
with current smokers, do sometimes occur in observational studies
when, as is often the case in Asia, quitting is generally recent.
However, this is merely an artefact caused by quitting among those
with incident disease,18 and benefits would be expected to appear
soon after quitting in disease-free populations.
It is important that tobacco control activities in Asia take
account of gender differences, because of the different causes of,
and perceptions about, smoking among Asian women and
men.29,30 The greater relative impact of cigarette smoking, on
women’s cardiovascular health, which we have demonstrated
is of particular public health concern given that the tobacco
epidemic is still spreading among women, with a peak not
expected for a few decades. If current trends are not halted, it is
estimated that there will be over 530 million female smokers by
2025.31 Furthermore, female smoking generally has a greater
impact on family health than does smoking among males.4 We
recommend that tobacco control policies should always, in
future, include messages specifically targeted at women.
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Commentary: Smoking and atherosclerotic
diseases in Asia—the implication in global
atherosclerosis prevention
KS Woo,* Thomas WC Yip, SK Kwong, Ping Chook and Leo CC Kum
Atherosclerotic disease including stroke and coronary artery
disease (CAD) is the most important health issue of modern
society. Cigarette smoking has been associated with this disease
in Western countries.1 In comparison, the impact of smoking on
cardiovascular health has been less well documented in Asia,
and, in particular, its impact in China where the population at
risk currently comes up to one-quarter of the global population
is unclear. Interest in the impact of smoking in China is
inspired by the fact that although 70% of Chinese males smoke
(compared with current prevalence in the range 20–30% for
men in most Western populations), the prevalence of CAD in
Chinese men is one-quarter of that for Western men.2
Furthermore, there is evidence that young Chinese adults
have less arterial endothelial dysfunction (a novel surrogate
atherosclerosis marker predictive of cardiovascular outcome)
than white adults with similar direct or indirect exposure to
cigarette smoke.3 A second cross-sectional study, similarly using
a surrogate marker of cardiovascular disease [carotid intima-
media thickness (IMT)], found that Chinese adults who had
Western lifestyles had thicker IMT than native rural Chinese,
and that the detrimental effect of cigarette smoking on IMT was
greater in Westernized Chinese living in Hong Kong and Sydney
than it was in native rural Chinese.4 These differences suggest
a relative protection of Chinese from the effect of cigarette
smoking, possibly due to certain gene differences, which may
be modified by Westernization, and subscribe to a gene–
environment interaction process, or to an interaction between
smoking, changes in lifestyles, and other risk factors in the
process of Westernization. While evaluation of the underlying
lifestyles, dietary habits, and subsequently physiological and
biochemical changes related to such Westernization process are
awaited with much interest, these early results call for further
studies that examine and compare smoking-related effects in
acculturated migrant Chinese population with those in village
natives in mainland China.5
To illuminate this important health issue, the paper from the
Asian Pacific Cohort Studies Collaboration in this issue of
the journal6 addressed the problem from an epidemiological
perspective. With the strength of large numbers of subjects (n =
562 338) and, therefore, more precise estimates, they confirmed
that smoking is a risk factor for both coronary heart disease
(CHD) and stroke, independent of the effects of BMI, blood
pressure, and cholesterol, with the amelioration of the effects
after quitting. Of much interest and importance, Asians and
Caucasians (in Australia and New Zealand) had similar
increased proportional cardiovascular risk (relative risk) from
smoking cigarettes, and similar relative risk reduction from
quitting. Moreover young people and women had greater
relative risk of cardiovascular disease from smoking, but the
effect declined with age. This report also appropriately
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